Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...
While initially approved for diabetes, GLP-1 drugs are gaining new indications, including the large opportunity in ...
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...
Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...
BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...
Obesity is high and holding steady in the U.S. About 4 in 10 Americans have obesity overall and about 1 in 10 have severe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback